Literature DB >> 19032450

Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C.

Satoru Yatsuji1, Etsuko Hashimoto, Maki Tobari, Makiko Taniai, Katsutoshi Tokushige, Keiko Shiratori.   

Abstract

BACKGROUND AND AIM: Ethnic differences in non-alcoholic steatohepatitis (NASH) are well-documented, but there has been no study on the prognosis of Japanese NASH patients with cirrhosis. Accordingly, we compared cirrhotic NASH with liver cirrhosis caused by chronic hepatitis C (LC-C) to clarify its clinical features and define the risk factors for death.
METHODS: A prospective evaluation of the outcomes of NASH patients with severe fibrosis was started in 1990. Data on age- and sex-matched patients with biopsy-proven LC-C were collected retrospectively and used as the control.
RESULTS: There were 68 patients with cirrhotic NASH and 69 with LC-C. The Child-Turcotte-Pugh (CTP) class was similar in these two groups. Although the outcome of the NASH group was better than that of the LC-C group, cirrhotic NASH followed a similar course to that of LC-C; that is, complications of cirrhosis developed, including hepatocellular carcinoma (HCC; the 5-year HCC rate was 11.3% for NASH and 30.5% for HCV) and death (the 5-year survival rates were 75.2% and 73.8%, respectively). HCC was the leading cause of death in both groups (NASH, 47%; HCV, 68%). The occurrence of HCC and the CTP class were significant risk factors for mortality in NASH patients according to a multivariate analysis (HCC: hazard ratio [HR] 7.96, 95% confidence interval [CI] 2.45-25.88, CTP class A: HR 0.17, 95% CI 0.06-0.50).
CONCLUSION: In conclusion, the present study confirmed that cirrhotic NASH has a similar course to LC-C. The occurrence of HCC was the strongest predictor of mortality in the NASH groups. These findings may be helpful when deciding on therapeutic interventions for NASH and also for the daily management of these patients.

Entities:  

Mesh:

Year:  2008        PMID: 19032450     DOI: 10.1111/j.1440-1746.2008.05640.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  106 in total

Review 1.  Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review.

Authors:  Yoshitaka Takuma; Kazuhiro Nouso
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

2.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

Review 3.  Nonalcoholic fatty liver disease in Asia: emerging perspectives.

Authors:  Wai-Kay Seto; Man-Fung Yuen
Journal:  J Gastroenterol       Date:  2016-09-16       Impact factor: 7.527

Review 4.  Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease.

Authors:  Nobuyuki Toshikuni; Mikihiro Tsutsumi; Tomiyasu Arisawa
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

5.  Value of shear wave velocity measurements for the risk assessment of hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease : HCC risk assessment by VTTQ.

Authors:  Masaaki Takamura; Tsutomu Kanefuji; Takeshi Suda; Takeshi Yokoo; Hiroteru Kamimura; Atsunori Tsuchiya; Kenya Kamimura; Yasushi Tamura; Masato Igarashi; Hirokazu Kawai; Satoshi Yamagiwa; Minoru Nomoto; Yutaka Aoyagi
Journal:  Hepatol Int       Date:  2014-03-01       Impact factor: 6.047

Review 6.  Is That Possible to Stop or Cease the NASH to Turn into HCC?

Authors:  Ahmet Uygun
Journal:  J Gastrointest Cancer       Date:  2017-09

Review 7.  Dietary habits and behaviors associated with nonalcoholic fatty liver disease.

Authors:  Kenichiro Yasutake; Motoyuki Kohjima; Kazuhiro Kotoh; Manabu Nakashima; Makoto Nakamuta; Munechika Enjoji
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

8.  Etiology of liver cirrhosis in Japan: a nationwide survey.

Authors:  Kojiro Michitaka; Shuhei Nishiguchi; Yutaka Aoyagi; Yoichi Hiasa; Yoshio Tokumoto; Morikazu Onji
Journal:  J Gastroenterol       Date:  2009-09-30       Impact factor: 7.527

Review 9.  Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality.

Authors:  Nobuyuki Toshikuni; Tomiyasu Arisawa; Mikihiro Tsutsumi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 10.  The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD).

Authors:  Qing Liu; Stig Bengmark; Shen Qu
Journal:  Lipids Health Dis       Date:  2010-04-28       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.